Introducing the latest innovation in wound care, Axio Biosolutions, a biotech startup backed by Ratan Tata’s RNT Capital, has launched MaxioCel, a next generation wound care dressing made of chitosan. Dr. V. S. Bedi, Director and Chairman, Vascular and Endovascular Department, Sir Gangaram Hospital, launched MaxioCel at the ‘Endovascular Live 2019’ at Pullman Novotel, New Delhi.
In 2018 Axio had become the first Indian company to get USFDA clearance for its innovative hemostatic dressing – Axiostat. With MaxioCel, the next generation Chitosan-based advance wound care product range, Axio is poised to further disrupt the wound care market. The ‘first of its kind’ product is expected to provide comfort and faster healing to patients suffering from chronic wounds, such as pressure ulcers, diabetic foot ulcers, venous leg ulcers, cavity wounds, skin abrasions, donor sites and post-operative surgical wounds, to name some.
Unique, 360-degree advanced wound management solution, MaxioCel was launched before a rapt audience of over 300 renowned vascular and endovascular surgeons, interventional radiologists, interventional cardiologists, podiatrists and general surgeons at ‘Endovascular Live 2019’. A paper was presented by Dr. Srujal Shah on experience of using MaxioCel. The presentation mentioned various cases done using MaxioCel range of products – Venous ulcers, diabetic foot ulcers and other complex wounds.
Commenting on the product launch, Dr. Srujal Shah (M. Ch.), Vascular & Endovascular Surgeon, IndoVasc Hospital, said, “There is a colossal increase in the number of patients suffering from chronic wounds. However, there are no products in wound care management that provide substantial relief from the high levels of discomfort and pain endured by patients. MaxioCel range of advanced chitosan dressings have the potential to address this gap and be a true game changer. The medical fraternity needs to embrace technological innovations happening in advance wound care management space in order to improve the quality of life of patients with chronic wounds.”
Leo Mavely, CEO, Axio Biosolutions, further added, “With the latest addition of MaxioCel to our product portfolio, we now have a complete range of innovative products spanning pre-hospital, intra-operative and post-operative clinical needs. India is becoming a world diabetic capital with millions of patients needing advanced wound care products every year. MaxioCel fulfils a large gap in the market with its combined hemostatic, pain management and scar improvement properties. We are proud to bring this product as an Indian innovation in wound care for the world market.”
Axio Biosolutions is a medtech company with focus on biomaterials. Its first product range Axiostat is a USFDA and CE approved product that stops bleeding instantly. Catering to the Indian Armed Forces, BSF, NSG, para-military forces, hospitals and emergency services not only in India, but across the globe, the home-grown first aid solution has prevented countless deaths due to haemorrhage and grievous injuries.
Headquartered in Cambridge, Axio Biosolutions has its corporate office in Bengaluru. The company has manufacturing facility in Ahmedabad and has strong R&D with multiple patents to its credit. Last year, Axio Biosolutions raised $7.4mn in a Series B funding round led by Ratan Tata’s UC- RNT, along with existing investors Accel Partners and IDG Ventures India.
For over a year, *Laxman, a 61-year-old patient from Bengaluru, was suffering from multiple venous leg ulcers (VLUs). These open lesions, occurring between the knee and ankle joint in the presence of venous disease, are known to be rather painful and discomforting.
Within two weeks of using MaxioCel, Laxman found that there was immediate pain relief and significant reduction in exudate levels and therefore controlled infection. Besides, the antimicrobial effect, the wound healed at a much faster rate. Subsequent studies have established that MaxioCel is indeed an excellent chitosan wound dressing in patients suffering from VLUs.
Axio was founded in 2008 by Leo Mavely, a bioengineer to develop novel biopolymer-platform-based products for wound care. Axio has the distinction of being the first company from India to design, develop and commercialize an Emergency Haemostat for Trauma care. Vision of Axio is to develop affordable, high-impact medical products that can solve unmet healthcare needs of emerging markets. Controlling life-threatening bleeding continues to be the major cause of death from traumatic injuries.
Axiostat® is its flagship product developed to reduce the mortality due to traumatic bleeding. Axio is a ISO 13485 certified company with an experienced team focused on bringing high-impact medical products to markets world-over. Axio is funded by marquee investors such as Accel, IDG Ventures and UC-RNT. Axio is today a global name that uses innovative medical technology to create breakthrough products and save people’s lives. Axiostat is regularly used by Indian Armed forces, BSF, NSG, and other para-military forces, as part of their defense kit, during their operations at the border and conflict zones such as North-East.
Axio’s customers also include numerous government hospitals and reputed private institutions such as AIIMS, Manipal, Apollo, Breach Candy and Fortis among others.
Via ~ Business Wire India
Top Image – Axiobio @Facebook.com
Like this content? Sign up for our daily newsletter to get latest updates.
This site uses Akismet to reduce spam. Learn how your comment data is processed.
We Dont Spam !